NCT06630481Completed
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
Source: ClinicalTrials.gov · Last updated 8 Oct 2024
Brief summary (registry, in English)
1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival. 3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 462 (actual)
- First submitted
- 2 Oct 2024
- Start date
- 1 Jan 2009
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06630481
What you commit to
- Study type: Observational
- Participants enrolled: 462
- From 1 Jan 2009 to the primary completion date, 31 Dec 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who underwent palliative surgery
- Patients who received NAT outside the specified protocol due to incomplete information.
Other
- Patients without a reported CAP grade
Who the study is looking for
- Adult patients (aged \>18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023.
- Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.